The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AMLSabine Käyser, Konstanze Döhner, Jürgen Krauter et al.|Blood|2010Cited by 485
<i>RUNX1</i>Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study GroupVerena I. Gaidzik, Konstanze Döhner, Lars Bullinger et al.|Journal of Clinical Oncology|2011Cited by 450
Monitoring of Minimal Residual Disease in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study GroupJan Krönke, Konstanze Döhner, Richard F. Schlenk et al.|Journal of Clinical Oncology|2011Cited by 393
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Brigitte Schlegelberger, Marcus Müller et al.|Leukemia|2017Cited by 339
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid LeukemiaRüdiger Hehlmann, Susanne Saußele, Michael Lauseker et al.|Journal of Clinical Oncology|2011Cited by 323